Current Atherosclerosis Reports最新文献_第9页

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress. 2023年欧洲心脏病学会大会上介绍的心血管疾病预防研究亮点

IF 5.8 2区医学

Current Atherosclerosis Reports Pub Date : 2023-12-01 Epub Date: 2023-11-17 DOI: 10.1007/s11883-023-01164-5

Kartik Gupta, Colin Hinkamp, Tyler Andrews, Chelsea Meloche, Abdul Mannan Khan Minhas, Leandro Slipczuk, Elizabeth Vaughan, Fatima Zohra Habib, Sana Sheikh, Dinesh Kalra, Salim S Virani

{"title":"Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress.","authors":"Kartik Gupta, Colin Hinkamp, Tyler Andrews, Chelsea Meloche, Abdul Mannan Khan Minhas, Leandro Slipczuk, Elizabeth Vaughan, Fatima Zohra Habib, Sana Sheikh, Dinesh Kalra, Salim S Virani","doi":"10.1007/s11883-023-01164-5","DOIUrl":"10.1007/s11883-023-01164-5","url":null,"abstract":"Purpose of review: To summarize selected late-breaking science on cardiovascular (CV) disease prevention presented at the 2023 European Society of Cardiology (ESC) congress.Recent findings: The NATURE-PARADOX was a naturally randomized trial that used genetic data from the UK Biobank registry to create \"cumulative exposure to low-density lipoprotein-cholesterol (LDL-C)\" biomarker and evaluate its association with major CV events regardless of plasma LDL-C levels or age. Safety and efficacy data of inclisiran, a PCSK9-interfering mRNA (PCSK9i) administered subcutaneously twice annually, were presented. Data on two new PCSK9is were presented, recaticimab, an oral drug, and lerodalcibep, a subcutaneous drug with a slightly different architecture than currently available PSCK9is. A phase 1 trial on muvalaplin, an oral lipoprotein (a) inhibitor, was presented. An atherosclerotic CV disease (ASCVD) risk prediction algorithm for the Asian population using SCORE2 data was presented. Long-term follow-up of patients enrolled in the CLEAR outcomes trial showed sustained and more significant ASCVD risk reduction with bempedoic acid in high-risk patients. The late-breaking clinical science at the 2023 congress of the ESC extends the known safety and efficacy data of a PCSK9i with the introduction of new drugs in this class. Using cumulative exposure to LDL-C rather than a single value will help clinicians tailor the LDL-C reduction strategy to individual risk and is an important step towards personalized medicine.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"965-978"},"PeriodicalIF":5.8,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136396760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How to Handle Elevated Triglycerides: Life after PROMINENT. 如何处理甘油三酯升高：PROMINENT 之后的生活。

IF 5.8 2区医学

Current Atherosclerosis Reports Pub Date : 2023-12-01 Epub Date: 2023-12-20 DOI: 10.1007/s11883-023-01175-2

Angela Pirillo, Alberico L Catapano

{"title":"How to Handle Elevated Triglycerides: Life after PROMINENT.","authors":"Angela Pirillo, Alberico L Catapano","doi":"10.1007/s11883-023-01175-2","DOIUrl":"10.1007/s11883-023-01175-2","url":null,"abstract":"Purpose of review: Hypertriglyceridaemia (HTG) is a common condition characterised by elevated levels of plasma triglycerides (TG), which are transported in the blood mainly by TG-rich lipoproteins (TRL). Elevated TG levels (150-400 mg/dL) are associated with increased cardiovascular risk. Severe HTG (>880 mg/dL) is associated with a risk of acute pancreatitis only. Randomised clinical trials investigating the clinical benefit of TG-lowering drugs in patients with elevated TG levels have provided conflicting results.Recent findings: Elevated TG levels are only one marker of altered lipid/lipoprotein metabolism and indeed reflect altered concentrations of one or more classes or subfractions of TRL, which in turn may have a different association with CV risk. Fibrates, the drugs most commonly used to treat HTG, provide cardiovascular benefits to only a specific subgroup of patients. The lack of clinical benefit from pemafibrate has emphasised the concept that lowering TG levels is not sufficient to reduce the CV risk unless it is accompanied by a reduction in the number of circulating atherogenic lipoproteins, which can be assessed by determining apolipoprotein B levels. Treatment with omega-3 fatty acids was also ineffective in reducing CV risk, with the exception of icosapent ethyl, which, however, appears to have beneficial effects beyond lipids. New drugs are currently being developed that aim to lower TG levels by targeting apolipoprotein C-III or angiopoietin-like-3, both of which are involved in the metabolism of TGs. TG reduction can be achieved by various drugs, but most of them are ineffective in reducing CV risk. The results of outcome studies on new TG-lowering drugs will clarify whether lowering apoB levels is critical to achieve clinical benefit.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"921-929"},"PeriodicalIF":5.8,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138799837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy? 2023年心力衰竭治疗:降脂治疗有一席之地吗?

IF 5.8 2区医学

Current Atherosclerosis Reports Pub Date : 2023-12-01 Epub Date: 2023-12-04 DOI: 10.1007/s11883-023-01166-3

Hana Poloczková, Jan Krejčí

引用次数: 0

Obesity and Dyslipidemia. 肥胖和血脂异常。

IF 5.8 2区医学

Current Atherosclerosis Reports Pub Date : 2023-12-01 Epub Date: 2023-11-18 DOI: 10.1007/s11883-023-01167-2

Barbora Nussbaumerova, Hana Rosolova

{"title":"Obesity and Dyslipidemia.","authors":"Barbora Nussbaumerova, Hana Rosolova","doi":"10.1007/s11883-023-01167-2","DOIUrl":"10.1007/s11883-023-01167-2","url":null,"abstract":"Purpose of review: This article sumarizes pathopysiological consequencies between obesity and dyslipidemia and aims to bring some practical approach.Recent findings: Dyslipidemia is often present in individuals with obesity and simultaneusly, many obese individuals have lipid metabolism disorders. Especially the abdominal obesity increases the cardiometabolic risk because of the presence of atherogenic dyslipidemia while the total low density lipoprotein cholesterol (LDL-C) may be normal. LDL-C is the primary goal in dyslipidemia treatment. Apoliprotein B (Apo B) and non - high density lipoprotein cholesterol (non-HDL-C) should be estimated to precise the cardiovascular risk and represents the secondary goal in treatment. Weight loss either with diet or antiobestic medication induces the decrease in triglycerides (TG) and LDL-C and the increase in HDL-C. Composition of nutrients, esp. fatty acids, influences lipid levels. Bariatric surgery is efficient in weight loss and has a significant effect on serum lipids. Dyslipidemia and obesity present common diseases that must be managed to decrease the cardiovascular risk and the risk of obesity-related complications.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"947-955"},"PeriodicalIF":5.8,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136396761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HDL as a Treatment Target: Should We Abandon This Idea? 将高密度脂蛋白作为治疗目标：我们应该放弃这个想法吗？

IF 5.8 2区医学

Current Atherosclerosis Reports Pub Date : 2023-12-01 Epub Date: 2023-12-05 DOI: 10.1007/s11883-023-01176-1

Floran Begue, Marie Laurine Apalama, Gilles Lambert, Olivier Meilhac

{"title":"HDL as a Treatment Target: Should We Abandon This Idea?","authors":"Floran Begue, Marie Laurine Apalama, Gilles Lambert, Olivier Meilhac","doi":"10.1007/s11883-023-01176-1","DOIUrl":"10.1007/s11883-023-01176-1","url":null,"abstract":"Purpose of review: High-density lipoproteins (HDL) have long been regarded as an antiatherogenic lipoprotein species by virtue of their role in reverse cholesterol transport (RCT), as well as their established anti-inflammatory and antioxidant properties. For decades, HDL have been an extremely appealing therapeutic target to combat atherosclerotic cardiovascular diseases (ASCVD).Recent findings: Unfortunately, neither increasing HDL with drugs nor direct infusions of reconstituted HDL have convincedly proven to be positive strategies for cardiovascular health, raising the question of whether we should abandon the idea of considering HDL as a treatment target. The results of two large clinical trials, one testing the latest CETP inhibitor Obicetrapib and the other testing the infusion of patients post-acute coronary events with reconstituted HDL, are still awaited. If they prove negative, these trials will seal the fate of HDL as a direct therapeutic target. However, using HDL as a therapeutic agent still holds promise if we manage to optimize their beneficial properties for not only ASCVD but also outside the cardiovascular field.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"1093-1099"},"PeriodicalIF":5.8,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138486944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sex Differences in Cardiac Transplantation. 心脏移植的性别差异。

IF 5.8 2区医学

Current Atherosclerosis Reports Pub Date : 2023-12-01 Epub Date: 2023-12-07 DOI: 10.1007/s11883-023-01169-0

Alice Chung, Heidi Hartman, Ersilia M DeFilippis

引用次数: 0

Emerging Preventive Strategies in Chronic Kidney Disease: Recent Evidence and Gaps in Knowledge. 慢性肾脏疾病的新兴预防策略:最新证据和知识空白。

IF 5.7 2区医学

Current Atherosclerosis Reports Pub Date : 2023-12-01 DOI: 10.1007/s11883-023-01172-5

Nishigandha Pradhan, Mirela Dobre

{"title":"Emerging Preventive Strategies in Chronic Kidney Disease: Recent Evidence and Gaps in Knowledge.","authors":"Nishigandha Pradhan, Mirela Dobre","doi":"10.1007/s11883-023-01172-5","DOIUrl":"10.1007/s11883-023-01172-5","url":null,"abstract":"Purpose of review: Chronic kidney disease (CKD) is increasingly prevalent worldwide and is associated with increased cardiovascular risk. New therapeutic options to slow CKD progression and reduce cardiovascular morbidity and mortality have recently emerged. This review highlights recent evidence and gaps in knowledge in emerging CKD preventive strategies.Recent findings: EMPA-Kidney trial found that empagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i) led to 28% lower risk of progression of kidney disease or death from cardiovascular causes, compared to placebo. This reinforced the previous findings from DAPA-CKD and CREDENCE trials and led to inclusion of SGLT2i as the cornerstone of CKD preventive therapy in both diabetic and non-diabetic CKD. Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, slowed diabetic kidney disease progression by 23% compared to placebo in a pool analysis of FIDELIO-DKD and FIGARO-DKD trials. Non-pharmacological interventions, including low protein diet, and early CKD detection and risk stratification strategies based on novel biomarkers have also gained momentum. Ongoing efforts to explore the wealth of molecular mechanisms in CKD, added to integrative omics modeling are well posed to lead to novel therapeutic targets in kidney care. While breakthrough pharmacological interventions continue to improve outcomes in CKD, the heterogeneity of kidney diseases warrants additional investigation. Further research into specific kidney disease mechanisms will facilitate the identification of patient populations most likely to benefit from targeted interventions.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"1047-1058"},"PeriodicalIF":5.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138458467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Natural Sirtuin1 Activators and Atherosclerosis: an Overview. 天然Sirtuin1激活剂与动脉粥样硬化:综述。

IF 5.8 2区医学

Current Atherosclerosis Reports Pub Date : 2023-12-01 DOI: 10.1007/s11883-023-01165-4

Karolina Łanoszka, Nimasha Vlčková

{"title":"Natural Sirtuin1 Activators and Atherosclerosis: an Overview.","authors":"Karolina Łanoszka, Nimasha Vlčková","doi":"10.1007/s11883-023-01165-4","DOIUrl":"10.1007/s11883-023-01165-4","url":null,"abstract":"Purpose of review: The purpose of this review is to summarize the most recent findings investigating the impact of several natural sirtuin (SIRT) activators, particularly SIRT1, on atherosclerosis.Recent findings: Sirtuins that belong to a family of class III histone deacetylases are believed to be novel therapeutic targets to treat age-related and chronic diseases. SIRT expression is regulated by small molecules called SIRT-activating compounds that can be found in natural food products. SIRT1 may exert protective effects in atherosclerosis, which is said to be a major cause of cardiovascular diseases. Most of the evidence supporting the beneficial effects of these natural compounds comes from in vitro or animal-based studies, while there have been particularly few or inconsistent human-based studies evaluating their long-term impact in recent years. SIRT1 activation has been demonstrated to mitigate or prevent atherosclerosis through various mechanisms. However, further research is required to determine the optimal SIRT activator dosage and to establish a stronger correlation between health effects and the administration of bioactive compounds. Additionally, conducting more human clinical trials is necessary to ensure the safety of these compounds for preventing atherosclerosis development.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"979-994"},"PeriodicalIF":5.8,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10770200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138458468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Polycystic Ovarian Syndrome: a Risk Factor for Cardiovascular Disease. 多囊卵巢综合征:心血管疾病的危险因素。

IF 5.8 2区医学

Current Atherosclerosis Reports Pub Date : 2023-12-01 Epub Date: 2023-12-04 DOI: 10.1007/s11883-023-01168-1

Yulith Roca Alvarez, Madison Pico, Namrita Ashokprabhu, Kareem Abou-Amro, Samantha Bailey, Elizabeth Pung, Evan Oberholster, Odayme Quesada

引用次数: 0

Sex Differences in Familial Hypercholesterolemia. 家族性高胆固醇血症的性别差异。

IF 5.8 2区医学

Current Atherosclerosis Reports Pub Date : 2023-11-01 Epub Date: 2023-10-10 DOI: 10.1007/s11883-023-01155-6

Marianne Klevmoen, Janneke W C M Mulder, Jeanine E Roeters van Lennep, Kirsten B Holven

{"title":"Sex Differences in Familial Hypercholesterolemia.","authors":"Marianne Klevmoen, Janneke W C M Mulder, Jeanine E Roeters van Lennep, Kirsten B Holven","doi":"10.1007/s11883-023-01155-6","DOIUrl":"10.1007/s11883-023-01155-6","url":null,"abstract":"Purpose of review: This review aims to summarize the existing research on sex differences in familial hypercholesterolemia (FH) across the lifespan.Recent findings: From childhood onward, total- and low-density lipoprotein cholesterol (LDL-C) levels in girls are higher than those in boys with FH. By the age of 30 years, women with FH have a higher LDL-C burden than men. In adulthood, women are diagnosed later than men, receive less lipid-lowering treatment, and consequently have higher LDL-C levels. An excessive atherosclerotic cardiovascular disease risk is reported in young female compared to male FH patients. The periods of pregnancy and breastfeeding contribute to treatment loss and increased cholesterol burden. Earlier initiation of treatment, especially in girls with FH, and lifelong treatment during all life stages are important. Future research should aim to recruit both women and men, report sex-specific data, and investigate the impact of the female life course on cardiovascular outcomes. Future guidelines should include sex-specific aspects.","PeriodicalId":10875,"journal":{"name":"Current Atherosclerosis Reports","volume":" ","pages":"861-868"},"PeriodicalIF":5.8,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618303/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41182273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0